Dragan Grabulovski is currently a pharmaceutical biotechnology advisor at Grabulovski Consulting Services. With a master’s degree in pharmaceutical sciences and a Doctor of Sciences from the ETH Zurich, he was the CSO and co-founder of Covagen AG, a Swiss biotech company acquired in 2014 by Cilag GmbH International, a division of the Janssen Pharmaceutical Companies of Johnson & Johnson. He was also instrumental in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2013/2014 attracting renowned investors (GIMV, Edmond de Rothschild Investment Partners, Novartis Venture Fund and others). He was the main inventor of the Fynomer technology, established a portfolio of novel bispecific FynomAb product candidates and managed the pipeline. He is a co-author of several peer-reviewed articles, reviews, book chapters, patent applications and granted patents